Home > Healthcare > Pharmaceuticals > Finished Drug Form > Hydroxyzine Market

Hydroxyzine Market Share

Report ID: GMI9267
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Hydroxyzine Market Share

The hydroxyzine sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Hydroxyzine Market Companies

Some of the eminent market participants operating in the hydroxyzine industry include:

Alliance Pharma Plc
Amneal Pharmaceuticals, Inc.
Aurobindo Pharma Limited
Glenmark Pharmaceuticals Ltd.
MYLAN N.V.
Novartis AG
Pfizer Inc.
Piramal Enterprises Limited
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for hydroxyzine was valued at USD 784.4 million in 2023 and is estimated to grow at 5.4% CAGR from 2024 to 2032, driven by increasing allergic reaction among the target population.

The tablets segment in the hydroxyzine market is likely to reach USD 557.1 million by 2032, propelled by the advancements in pharmaceutical formulation technologies that enhance the bioavailability and efficacy of hydroxyzine tablets.

The U.S. market size was USD 290 million in 2023, owing to continuous innovation by pharmaceutical companies in the country.

Alliance Pharma Plc, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., MYLAN N.V., Novartis AG, Pfizer Inc., Piramal Enterprises Limited, Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Limited.